To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Synaptic vesicle protein … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies.

Review article
Authors Kerstin Heurling
Nicholas Ashton
Antoine Leuzy
Eduardo R Zimmer
Kaj Blennow
Henrik Zetterberg
Jonas Eriksson
Mark Lubberink
Michael Schöll
Published in Molecular and cellular neurosciences
ISSN 1095-9327
Publication year 2019
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Wallenberg Centre for Molecular and Translational Medicine
Language en
Subject categories Radiology, Nuclear Medicine and Medical Imaging, Neurosciences, Other Medical Biotechnology


Measuring synaptic density in vivo using positron emission tomography (PET) imaging-based biomarkers targeting the synaptic vesicle protein 2A (SV2A) has received much attention recently due to its potential research and clinical applications in synaptopathies, including neurodegenerative and psychiatric diseases. Fluid-based biomarkers in proteinopathies have previously been suggested to provide information on pathology and disease status that is complementary to PET-based measures, and the same can be hypothesized with respect to SV2A. This review provides an overview of the current state of SV2A PET imaging as a biomarker of synaptic density, the potential role of fluid-based biomarkers for SV2A, and related future perspectives.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?